# MEDI4736 and Tremelimumab in Treating Patients With Metastatic HER2 Negative Breast Cancer

> **NCT02536794** · PHASE2 · COMPLETED · sponsor: **Northwestern University** · enrollment: 30 (actual)

## Conditions studied

- Estrogen Receptor Negative
- Estrogen Receptor Positive
- HER2/Neu Negative
- Recurrent Breast Carcinoma
- Stage IV Breast Cancer

## Interventions

- **BIOLOGICAL:** Anti-B7H1 Monoclonal Antibody MEDI4736
- **OTHER:** Laboratory Biomarker Analysis
- **OTHER:** Pharmacological Study
- **BIOLOGICAL:** Tremelimumab

## Key facts

- **NCT ID:** NCT02536794
- **Lead sponsor:** Northwestern University
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2016-01-14
- **Primary completion:** 2020-02-06
- **Final completion:** 2021-01-22
- **Target enrollment:** 30 (ACTUAL)
- **Last updated:** 2022-05-17

## Collaborators

- [object Object]
- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02536794

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02536794, "MEDI4736 and Tremelimumab in Treating Patients With Metastatic HER2 Negative Breast Cancer". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT02536794. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*